Roberto Guzmán
YOU?
Author Swipe
SUSTAINABLE SOLUTIONS FOR INDUSTRIAL WASTEWATER MANAGEMENT USING PERMEABLE CONCRETE AND WATER REUSE FOR FLEET WASHING WITHIN THE FRAMEWORK OF THE CIRCULAR ECONOMY: CASE OF THE COMPANY CONCRETOS DE SINCELEJO Open
One of the main environmental problems in Sincelejo (Sucre) is the inadequate disposal of industrial wastewater, much of which is discharged untreated into the urban drainage system, affecting surface and groundwater bodies. This research …
PHYSICO-CHEMICAL AND ELECTROCHEMICAL DELIGNIFICATION AS A PRETREATMENT OF LIGNOCELLULOSIC BIOMASS FOR DIFFERENT APPLICATIONS: A MINI-REVIEW Open
In recent years, the applications of lignocellulosic biomass (LCB) have substantially increased due to its versatility in different areas of study and interest. Therefore, it is evident that the delignification pretreatment of LCB is funda…
Supplementary Table S5 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies Open
Binding coverage of BMS-986351 across the six major SIRPα haplotypes
Supplementary Figure S5 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies Open
Lack of BMS-986351 effect on NK-mediated ADCC of tumors cells (A), autologous normal monocytes and unactivated CD4 cells (B), and autologous ADCP activity on monocytes and T cells (C).
Supplementary Figure S2 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies Open
Baseline CD47 expression by flow cytometry in colorectal cancer cell lines (A) and in DLBCL cell lines (B).
Supplementary Table S6 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies Open
Pearson correlation coefficient (cc) of SIRPA expression vs each macrophage-related gene in each of the separate TCGA cohorts, sorted high to low based on the mean of the correlation coefficients
FIGURE 3 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies Open
Gene expression data from TCGA across four indications (COAD = colon adenocarcinoma, DLBC = diffuse large B-cell lymphoma, HNSC = head and neck cancer, READ = rectal adenocarcinoma) with each point from one patient and expression units sho…
Supplementary Figure S1 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies Open
CD47 gene expression across all of TCGA, shown with a boxplot for each indication (A), and a scatterplot showing the expression of SIRPA compared to the average macrophage gene expression (mean of CD163, CSF1R, CD14 and CD68 gene expressio…
Supplementary Figure S4 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies Open
Enhanced phagocytosis in OCI-Ly3 cells is achieved when BMS-986351 is combined with rituximab.
TABLE 1 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies Open
Pharmacokinetics of BMS-986351 in cynomolgus monkeys (n = 3) after dosing on day 1 and day 15 (values shown are means of repeated measurements)
Supplementary Table S6 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies Open
Pearson correlation coefficient (cc) of SIRPA expression vs each macrophage-related gene in each of the separate TCGA cohorts, sorted high to low based on the mean of the correlation coefficients
FIGURE 5 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies Open
Cross-reactivity of BMS-986351 in human (A), cynomolgus monkey (B), rat (C), and mouse (D). E, Immunophenotyping by multiparameter flow cytometry in human and cynomolgus monkeys shows that most CD14-positive cells (monocytes) also bind BMS…
Supplementary Table S3 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies Open
Inhibition of CD47–SIRPα binding by serially-diluted BMS-986351, as determined by surface plasmon resonance
Supplementary Table S5 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies Open
Binding coverage of BMS-986351 across the six major SIRPα haplotypes
FIGURE 3 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies Open
Gene expression data from TCGA across four indications (COAD = colon adenocarcinoma, DLBC = diffuse large B-cell lymphoma, HNSC = head and neck cancer, READ = rectal adenocarcinoma) with each point from one patient and expression units sho…
TABLE 1 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies Open
Pharmacokinetics of BMS-986351 in cynomolgus monkeys (n = 3) after dosing on day 1 and day 15 (values shown are means of repeated measurements)
Supplementary Table S2 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies Open
Binding affinity of SIRPα, SIRPβ, and SIRPγ, as determined by surface plasmon resonance
Supplementary Figure S4 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies Open
Enhanced phagocytosis in OCI-Ly3 cells is achieved when BMS-986351 is combined with rituximab.
Supplementary Table S7 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies Open
Incidences of CD163-positive macrophages and CD66b-positive neutrophil infiltrates in CRC, SCCHN, and DLBCL (A). Summary incidences of H-score values for SIRPα and EGFR in SCCHN (B) and DLBCL (C).
Supplementary Table S1 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies Open
Abundance of the most prevalent CD47–SIRPα binding interface haplotypes
Supplementary Figure S3 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies Open
Rituximab dose selection based on macrophage phagocytosis in CD20-positive NHL cell lines. Data showed that a rituximab dose of 0.1 nM induced maximal phagocytosis in OCI-Ly3 cells.
Supplementary Figure S2 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies Open
Baseline CD47 expression by flow cytometry in colorectal cancer cell lines (A) and in DLBCL cell lines (B).
Supplementary Figure S5 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies Open
Lack of BMS-986351 effect on NK-mediated ADCC of tumors cells (A), autologous normal monocytes and unactivated CD4 cells (B), and autologous ADCP activity on monocytes and T cells (C).
Supplementary Figure S1 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies Open
CD47 gene expression across all of TCGA, shown with a boxplot for each indication (A), and a scatterplot showing the expression of SIRPA compared to the average macrophage gene expression (mean of CD163, CSF1R, CD14 and CD68 gene expressio…
FIGURE 4 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies Open
Effect of BMS-986351, alone or in combination with rituximab, on the proportion of phagocytic macrophages in ABC (A) and GCB (B) cell lines. ABC, activated B cell; GCB, germinal center B cell.
FIGURE 5 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies Open
Cross-reactivity of BMS-986351 in human (A), cynomolgus monkey (B), rat (C), and mouse (D). E, Immunophenotyping by multiparameter flow cytometry in human and cynomolgus monkeys shows that most CD14-positive cells (monocytes) also bind BMS…
FIGURE 2 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies Open
Binding affinity of BMS-986351 to SIRPα (A), SIRPβ (B), and SIRPγ (C) as determined by SPR and inhibition of CD47-SIRPα binding (D). E, Cocrystallization of BMS-986351 with SIRPα (structure available in the Protein Data Bank, entry 7ST5) i…
Supplementary Figure S3 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies Open
Rituximab dose selection based on macrophage phagocytosis in CD20-positive NHL cell lines. Data showed that a rituximab dose of 0.1 nM induced maximal phagocytosis in OCI-Ly3 cells.
Data from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies Open
In normal cells, binding of the transmembrane protein CD47 to signal regulatory protein-α (SIRPα) on macrophages induces an antiphagocytic signal. Tumor cells hijack this pathway and overexpress CD47 to evade immune destruction. Macrophage…
Supplementary Table S7 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies Open
Incidences of CD163-positive macrophages and CD66b-positive neutrophil infiltrates in CRC, SCCHN, and DLBCL (A). Summary incidences of H-score values for SIRPα and EGFR in SCCHN (B) and DLBCL (C).